"Did you have permission to use Havasupai blood for your research?" At the heart of this case is a conflict of interests between scientists at powerful institutions that stand to profit from DNA research and powerless members of an underclass.
Until now, American medicine as a profession has turned a blind eye and deaf ear to ghostwritten journal articles that have corrupted the integrity of the medical literature, displacing science-based medicine with corporate propaganda masquerading as science.
Colonel Coots: "It is a significant breach of academic protocol. It’s a breach of trust."
Merck is reported to have created a fake "peer-reviewed" journal to present favorable data that made its potentially fatal drugs–Fosamax and Vioxx–look good.
A series of slides, all prepared by Dr. Biederman–according to his sworn testimony–are revealing as they raise serious doubts about the scientific and ethical integrity of his oeuvre.
The disconnect provides further evidence of how the prescription drug industry can shape, revise or even conceal negative research findings that affect the way doctors prescribe.
The efficacy and safety of a new drug that treats a serious and life threatening illness in premature infants will be studied versus sham/placebo in Latin America. The sponsor plans to apply for FDA approval, in addition to local and European registration. There are approved therapies (surfactants) for this illness (Respiratory Distress Syndrome, or RDS) in those countries where this trial is proposed to take place, and surfactants are even used in some of their hospitals. However, surfactants are completely unavailable to infants at many other hospitals, secondary to rationing or economic limitations.
Are you aware that if you are in an accident in the U.S. your organs may be surgically removed without your consent?
In essence FDA proposals merely change the seating arrangement on the deck of the sinking Titanic. Eli Lilly announced that it intends to seek FDA approval for a long-lasting injectable form of Zyprexa (taken once a month).
The FDA is salivating in expectation of increased funding from the drug industry–ostensibly to speed up the reviewing process for TV ads.
Unssuccessful effort to engage debate within the community of the authorized clinical research gatekeepers charged with protecting the safety and welfare of the human subjects of research–i.e., members of institutional review boards (IRBs–REBs in Canada).
The ethics of this radical drug experiment is being challenged by Dr. Jerald Block, a forthright psychiatrist and experienced system's analyst. His critical appraisal, published in the Bioethics Forum, Hastings Center Report.
